Giant Cell Arteritis (GCA) Clinical Trials

12 recruiting

Giant Cell Arteritis (GCA) Trials at a Glance

11 actively recruiting trials for giant cell arteritis (gca) are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Bonn, Paris, and Dijon. Lead sponsors running giant cell arteritis (gca) studies include University of Bonn, Groupe français d'étude des Maladies Inflammatoires de loeil, and Groupe Hospitalier de la Rochelle Ré Aunis.

Browse giant cell arteritis (gca) trials by phase

Treatments under study

About Giant Cell Arteritis (GCA) Clinical Trials

Looking for clinical trials for Giant Cell Arteritis (GCA)? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Giant Cell Arteritis (GCA) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Giant Cell Arteritis (GCA) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting

The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant Cell Arteritis.

Giant Cell Arteritis (GCA)
Vastra Gotaland Region340 enrolled1 locationNCT07246577
Recruiting
Phase 2

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Giant Cell Arteritis (GCA)
National Institute of Allergy and Infectious Diseases (NIAID)78 enrolled7 locationsNCT07108387
Recruiting
Phase 2

Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)

Giant Cell Arteritis (GCA)Takayasu ArteritisLarge Vessel Vasculitis
University of Edinburgh60 enrolled1 locationNCT06887062
Recruiting
Phase 4

Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment

Adrenal InsufficiencyGiant Cell Arteritis (GCA)Polymyalgia Rheumatica (PMR)
Marianne Andersen100 enrolled3 locationsNCT05193396
Recruiting
Not Applicable

oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound

Giant Cell Arteritis (GCA)
Hôpital NOVO190 enrolled9 locationsNCT07001059
Recruiting

Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)

Giant Cell Arteritis (GCA)Polymyalgia Rheumatica (PMR)
Centre Hospitalier Universitaire Dijon78 enrolled1 locationNCT06609668
Recruiting

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Sclerosis (SSc)+10 more
University of Bonn120 enrolled1 locationNCT07150000
Recruiting

Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis

Giant Cell Arteritis (GCA)
Groupe Hospitalier de la Rochelle Ré Aunis100 enrolled1 locationNCT06742671
Recruiting

AYLo - AutoimmunitY and Loss of y

Asthma BronchialeCOPDSarcoidosis+10 more
University of Bonn500 enrolled1 locationNCT06696027
Recruiting

Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis

Giant Cell Arteritis (GCA)Polymyalgia Rheumatica (PMR)
University Hospital, Basel, Switzerland30 enrolled1 locationNCT05479448
Recruiting

TocILizumab in aorTitis in GCA (TILT)

Giant Cell Arteritis (GCA)Aortitis
Groupe français d'étude des Maladies Inflammatoires de loeil80 enrolled1 locationNCT06271018